Dialybrid is a medical equipment and technology manufacturer focused on hybrid technologies for cardiovascular tissue engineering. The company's headquarters are located in Cantù and Milan, Italy.
Subscribe to see Dialybrid’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Dialybrid is a medical devices company headquartered in Italy. Its most recent funding round, Series A, raised $16.5M in October 2026. Xcout tracks 1 named person at Dialybrid, including Francesco Giovanni Greco (CEO).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $16.5M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Dialybrid's closest competitors — see the full list of competitors and alternatives →
Becton Dickinson Italia S.p.A. is an Italian subsidiary and corporate entity with its headquarters located in Milan, Italy.
Vascudyne, Inc. is a bioengineered tissue technology company specializing in cardiovascular medicine, including heart valve manufacturing and engineered tissue solutions.
CorMatrix Cardiovascular, Inc. is a medical technology company headquartered in Roswell and Atlanta, Georgia. The company researches, develops, and commercializes platform biomedical technologies, such as CorMatrix and CanGaroo, for cardiovascular applications.
BiomimX Srl is a biotech company headquartered in Milan, Italy, operating out of the MIND – Milano Innovation District. The company relies on proprietary uBeat technology, a breakthrough actuator patented by Politecnico di Milano, to develop advanced biological models.
Test Industry is a machinery manufacturing company headquartered in Milan, Italy, that specializes in industrial test benches and testing machines.
Defymed is a medical technology company located in the Grand-Est region of France. The company focuses on the development of medical devices and bio-artificial organs designed to treat chronic diseases such as diabetes.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Dialybrid? Suggest a correction · Work at Dialybrid? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.